Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,369 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT07284277RecruitingPhase 1/Phase 2
TTFields and chemo for metastatic pancreatic cancer
This trial tests a wearable device (TTFields) combined with a specific chemotherapy (mFOLFIRINOX) for people whose pancreatic cancer has spread to the liver and other organs. The device sends gentle electrical fields to disrupt cancer cell growth, and the chemo attacks cancer cells throughout the body.
Pamplona, NavarreAges 18 years+ - NCT07291297RecruitingPhase 2
Metformin plus standard therapy for soft tissue sarcoma
This trial tests adding metformin, a common diabetes drug, to the usual first cancer treatment for advanced soft tissue sarcoma. It may help the standard therapy work better.
Charlotte, North CarolinaAges 18 years+ - NCT07297134Recruiting
PTEN and Organ-Specific microRNAs in Breast Cancer
This trial looks at specific molecules (PTEN and microRNAs) in the blood to see if they help doctors understand how breast cancer spreads. If you have breast cancer (whether it has spread or not) or are healthy, you might be eligible.
Istanbul, IstanbulAges 18 years+ - NCT07302763Recruiting
PET imaging to track prostate cancer changes
This study uses special PET scans (up to 4 times) to see how metastatic prostate cancer changes over time. It is for people whose cancer has spread and is still growing after hormone treatments, and who are planning to start chemotherapy or PSMA therapy.
Québec, QuebecAges 18 years+ - NCT07309289RecruitingPhase 3
Comparing two drug combos for first-line metastatic colorectal cancer
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
ShanghaiAges 18 years+ - NCT07313306Recruiting
Exercise for symptom management in metastatic breast cancer
This study tests whether a structured exercise program can help manage symptoms like fatigue and pain in people with metastatic breast cancer. You’ll work with a coach to safely increase your physical activity level.
Chapel Hill, North CarolinaAges 18 years+ - NCT07315854RecruitingPhase 2
Immunotherapy combo plus chemo for untreated stomach cancer
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07333066RecruitingPhase 3
Adding chemotherapy when first treatment response is limited
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
BayonneAges 18 years+ - NCT07339267RecruitingPhase 1
Safety and dosing study of ASP5541 in Chinese men with metastatic prostate cancer
This study tests a new drug called ASP5541 for Chinese men with prostate cancer that has spread. The drug is given as a shot, and researchers want to see if it is safe and what the right dose might be.
Beijing, Beijing MunicipalityAges 18–85 - NCT07339878Recruiting
Choosing the first treatment for advanced bladder cancer
This study looks at the different ways doctors choose the first treatment for patients whose urothelial cancer has spread. It aims to understand what factors influence that choice, which could help improve care for future patients.
StrasbourgAges 18 years+ - NCT05376878RecruitingPhase 4
PET/MRI scan to guide treatment in HER2+ brain metastatic breast cancer
This trial tests a special PET/MRI imaging scan using a labeled drug to help doctors evaluate HER2+ breast cancer that has spread to the brain. It focuses on patients who plan to receive fam-trastuzumab deruxtecan, a targeted cancer medicine, and aims to see how well the scan can support treatment decisions.
Duarte, CaliforniaAges 18 years+ - NCT04804644RecruitingPhase 3
Memory-sparing radiation for brain metastases in small cell lung cancer
This study tests whether focusing high-dose radiation only on brain tumor spots, while avoiding the hippocampus (a brain area important for memory), helps protect memory and thinking compared with standard whole-brain radiation. It’s for people with small cell lung cancer that has spread to the brain.
Phoenix, ArizonaAges 18 years+ - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07361003RecruitingPhase 3
Testing suvemcitug plus chemo for refractory colorectal cancer
This trial tests a new drug, suvemcitug, combined with an oral chemotherapy called FTD/TPI for people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT07389967Recruiting
Nutrition awareness study for women after breast cancer treatment
This study looks at how aware women are about nutrition after finishing their main breast cancer treatment. It aims to help improve support for diet and healthy eating habits.
Chapel Hill, North CarolinaAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07394062Recruiting
Comparing chemo-immunotherapy combinations for advanced lung cancer
This study compares two standard treatments for metastatic non-small cell lung cancer when the tumor has low levels of a protein called PD-L1. It looks at how well chemotherapy plus pembrolizumab works versus chemotherapy plus nivolumab and ipilimumab.
AnkaraAges 18 years+ - NCT02622581Recruiting
Lung cancer testing and treatment outcomes research study platform
This study collects information from adults with different types and stages of lung cancer to connect molecular test results with treatment choices and outcomes. It may help improve how lung cancer is diagnosed and managed by building a better understanding of what works for different patients.
OldenburgAges 18 years+ - NCT03129854Recruiting
ADT with or without freezing the prostate for spread cancer
This trial compares standard hormone therapy (ADT) alone versus ADT plus a procedure that freezes the prostate (cryoablation) in people whose prostate cancer has spread. It looks to see whether adding freezing improves outcomes while keeping treatment safe.
Guangzhou, GuangdongAges 18–90 - NCT03184038Recruiting
Testing brain function in people with brain metastases after radiosurgery
This study looks at how well your thinking and memory work after treatment with radiosurgery for brain metastases. It may help researchers understand which patients benefit best and how to monitor side effects on brain function.
Sewell, New JerseyAges 18 years+ - NCT06968988RecruitingPhase 1
Three-drug combo for advanced soft tissue sarcoma
This trial tests a new combination of three drugs (zanzalintinib, ipilimumab, and nivolumab) for people with soft tissue sarcoma that has spread. The goal is to see if this combination can shrink or slow the cancer.
St Louis, MissouriAges 18 years+ - NCT02600949Enrolling by invitationPhase 1
Peptide vaccine study for advanced pancreatic or colon cancer
This Phase 1 study tests a personalized vaccine made from a patient’s tumor to help the immune system recognize and attack cancer. It is for people with advanced pancreatic or colorectal cancer (often after surgery or while metastatic) and aims to see if the approach is safe and can help immune control of the cancer.
Houston, TexasAges 18 years+
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,369 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.